Filing identity and reporting period
Important discrepancy: The supplied filing is ARCA biopharma, Inc.’s Form 10-Q for the quarter ended September 30, 2021, not a filing for Oruka Therapeutics, Inc. The summary below reflects the filing text provided.
ARCA is a clinical-stage biopharmaceutical company with no product revenue. Its lead candidates are rNAPc2 (AB201), under study for hospitalized COVID-19 patients, and Gencaro, being developed for atrial fibrillation in patients with heart failure.
Financial results and liquidity
Amounts below are in millions of dollars unless noted.
| Metric | Q3 2021 | Q3 2020 | Nine months 2021 | Nine months 2020 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Research and development expense | 3.438 | 1.051 | 9.891 | 1.788 |
| General and administrative expense | 1.278 | 0.939 | 3.764 | 2.852 |
| Total costs and expenses | 4.716 | 1.990 | 13.655 | 4.640 |
| Net loss | (4.712) | (1.991) | (13.646) | (4.613) |
| Basic and diluted loss per share | $(0.33) | $(0.33) | $(0.99) | $(1.46) |
| Cash used in operating activities | Not provided quarterly | Not provided quarterly | 13.815 | 4.730 |
Because ARCA had no revenue, profit margins are not applicable. At September 30, 2021, cash and cash equivalents were $58.313 million, current assets were $59.666 million, current liabilities were $3.182 million, total liabilities were $3.592 million, and stockholders’ equity was $56.600 million. The company reported operating lease liabilities; the filing reports no material borrowing balance. Cash increased $9.242 million during the first nine months, reflecting $23.093 million of net financing cash inflow, principally from common-stock sales, offset by operating and investing cash use.
Changes versus comparable periods
- Q3 R&D expense rose $2.387 million year over year; nine-month R&D expense rose $8.103 million, primarily due to rNAPc2 clinical-trial and manufacturing-development activity.
- Q3 G&A expense increased $0.339 million and nine-month G&A increased $0.912 million, mainly from personnel and insurance costs.
- Nine-month net loss increased from $4.613 million to $13.646 million, while operating cash use increased from $4.730 million to $13.815 million.
- Cash was higher than at December 31, 2020, but the company raised $23.1 million net through stock issuance during the nine-month period. Shares outstanding increased from 9,548,150 at year-end 2020 to 14,410,143 at September 30, 2021.
Outlook, developments, and risks
- Management estimated that September 30 cash would fund operations through the end of fiscal 2022. A Phase 3 rNAPc2 trial or the Gencaro PRECISION-AF Phase 3 trial would likely require additional financing. Management cautioned that actual cash use could differ from its estimates.
- ARCA was enrolling patients in its international Phase 2b ASPEN-COVID-19 trial. In July 2021, it increased planned enrollment from 100 to 160. In October 2021, the data and safety monitoring committee recommended completing the trial without changing its design; management anticipated topline results in Q1 2022. These were expectations, not reported results.
- PRECISION-AF remained on hold, pending additional financing and improvement in the pandemic sufficient to support patient recruitment. The filing describes Gencaro’s Phase 3 program as requiring substantial additional capital.
- In July 2021, ARCA obtained exclusive worldwide patent rights related to rNAPc2 from the University Medical Center Mainz. Potential upfront and milestone obligations could total approximately €1.6 million, plus low-single-digit royalties if the product is approved and commercialized.
- ARCA had up to $50 million available under its amended at-the-market equity offering prospectus. Further equity financing could materially dilute shareholders; financing or strategic transactions might not be available on acceptable terms.
- Key risks include clinical-trial efficacy, safety and enrollment; regulatory approval; competition and changing COVID-19 treatment needs; reliance on third-party manufacturers and research organizations; intellectual-property protection; Nasdaq listing compliance; and the company’s ability to secure funding. The filing says the statements use a going-concern basis while warning that future funding uncertainty could affect continued operations.
- The filing reports no legal proceedings and states that disclosure controls were effective at a reasonable level of assurance, with no material quarterly change in internal control over financial reporting.
Most important facts for investors to verify
- Confirm the issuer: the supplied document identifies ARCA biopharma, Inc., not Oruka Therapeutics, Inc.
- Check subsequent ASPEN-COVID-19 trial results and whether a Phase 3 program was initiated, funded, or altered.
- Verify cash runway against actual operating cash burn, financing activity, and any later liquidity disclosures.
- Review the timing, funding, and status of PRECISION-AF and any Gencaro development plans.
- Assess dilution from additional equity issuance and the terms or availability of strategic financing.
- Confirm the status and financial terms of the Mainz patent agreement, including any payments or royalty obligations.